August 28, 2023
RQM+, a global leader in MedTech services, announces its acquisition of CRO Kottmann, a premier contract research organisation (CRO) renowned for its excellent customer service, scientific clinical research and quality in the key market of Germany. This significant move further supports RQM+’s dedication to strategic growth and presence in Europe and emphasizes its dominance in the growing areas of MedTech.
The integration of CRO Kottmann enhances RQM+’s existing geographical footprint in global operations as well as ensures comprehensive end-to-end support for clients, from pre-clinical phases to product commercialisation. The addition of CRO Kottmann further expands RQM+’s rapidly growing business as a leading MedTech CRO, driving both existing and new clients’ innovations into pivotal markets.
“We are tremendously excited about this pivotal acquisition. The synergy between RQM+ and CRO Kottmann will propel us to greater heights in the industry. The German market, well known for its emphasis on science, innovation, and market intelligence, is a vital geography for RQM+,” said RQM+ Chief Operating Officer of Clinical Trial Services, David Novotny. “With the combined expertise of both organisations, we will achieve quicker, more efficient operational deliveries that will facilitate a faster market entry for our clients.”
With a reputation for unparalleled customer service and quality, CRO Kottmann brings a wealth of industry-leading knowledge and acumen, positioning RQM+ to leverage these attributes in expanding its global influence, especially in Europe.
“We have always held a like-minded approach to ensuring best-in-class customer service and advisement. This alignment of core values, coupled with our shared ambition to foster growth in science and innovation, will make this partnership a continuation of the success story in Clinical Research. We are pleased to be able to offer our clients an even greater depth of clinical research services. Going forward, our clients can continue using our services to conduct global studies worldwide,” said Tanja Kottmann MD, CEO of CRO Kottmann.
As RQM+ continues its trajectory of growth, the acquisition of CRO Kottmann underscores its commitment to delivering unparalleled service to MedTech manufacturers of all sizes. The acquisition ensures a potent combination of regulatory and clinical experience, industry-leading capabilities, and unrivaled geographical reach, paving the way for swift and innovative solutions in the MedTech space.
Contact our Team Members advising in this transaction:
Translink Corporate Finance is an independent partnership of firms dedicated to Corporate Finance and M&A advisory services through over 35 offices in the key markets in Europe, North and South America, Asia, Australia, and Africa. Translink has been successful in advising clients on thousands of transactions since its founding in 1972 and Translink offices have acted as advisers in over 100 M&A projects during the last twelve months.
Dinan & Company, LLC is the partner firm of Translink Corporate Finance in the United States. It is a leading national M&A and merchant banking services company with over 35 years of advisory experience dedicated to middle-market transactions.
Translink Corporate Finance GmbH & Co. KG with its offices in Frankfurt and Bremen covers Translink’s business in Germany, Austria, and Switzerland. It is composed of seasoned finance and M&A professionals who have in-depth experience in a variety of sectors and disciplines.